Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETERMINE-Reduced: Dapagliflozin in HFrEF
NCT03877237Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of dapagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by AstraZeneca. Started Apr 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03877237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877237.